Janux Therapeutics/JANX

$47.91

-4.16%
-
1D1W1MYTD1YMAX

About Janux Therapeutics

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Ticker

JANX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Campbell

Employees

64

Headquarters

San diego, United States
Website
www.januxrx.com

JANX Metrics

BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$1.22
EPS
-
Beta
-
Dividend rate
$2.6B
$65.60
$5.65
1.1M
62.086
-10.67%
-11.5%
-10.95%
355.704
3.952
3.953
-19.67%
24.14%

What the Analysts think about JANX

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
36.57% upside
High $100.00
Low $25.00
$47.91
Current price
$65.43
Average price target

JANX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,225% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.2M
-50%
Net income
-$15M
25.64%
Profit margin
-1,225%
151.28%

JANX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.43%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.42
-$0.25
-$0.25
-$0.30
-
Expected
-$0.52
-$0.47
-$0.41
-$0.33
-$0.31
Surprise
-18.84%
-46.81%
-39.05%
-9.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Janux Therapeutics stock?

Janux Therapeutics (JANX) has a market cap of $2.6B as of May 15, 2024.

What is the P/E ratio for Janux Therapeutics stock?

The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of May 15, 2024.

Does Janux Therapeutics stock pay dividends?

No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of May 15, 2024.

When is the next Janux Therapeutics dividend payment date?

Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.

What is the beta indicator for Janux Therapeutics?

Janux Therapeutics (JANX) does not currently have a Beta indicator.

What is the Janux Therapeutics stock price target?

The target price for Janux Therapeutics (JANX) stock is $65.43, which is 36.57% above the current price of $47.91. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Janux Therapeutics stock

Buy or sell Janux Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing